SCHEMBL12615966

SCHEMBL12615966

Cc1ccc(S(=O)(=O)n2cc(-c3cccc(OC(C)C)n3)c3cc(-c4nnc(C)o4)ccc32)cc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 11/20 0.57
▸ PIM2 Q9P1W9 10/20 0.57
▸ PIM3 Q86V86 6/20 0.57
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ MAOA P21397 1/20 0.36
▸ MAOB P27338 1/20 0.36
▸ TP53 P04637 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ UBE2N P61088 1/20 0.34
▸ PTGDR Q13258 1/20 0.34
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.33
▸ EED O75530 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12614998 0.90 PIM1 (0.58) PIM1PIM2PIM3L3MBTL1MAOA
SCHEMBL12616328 0.82 PIM1 (0.57) PIM1PIM2PIM3L3MBTL1
SCHEMBL12615465 0.81 PIM1 (0.44) PIM1PIM2PIM3L3MBTL1KDM4E
SCHEMBL12615388 0.80 PIM1 (0.57) PIM1PIM2PIM3L3MBTL1KDM4E
SCHEMBL12615758 0.80 PIM1 (0.57) PIM1PIM2PIM3L3MBTL1KDM4E
SCHEMBL12615851 0.77 PIM1 (0.42) PIM1PIM2L3MBTL1TP53MAPT
SCHEMBL12615435 0.76 PIM1 (0.46) PIM1PIM2L3MBTL1MAOAMAOB
SCHEMBL12616108 0.75 PIM1 (0.51) PIM1PIM2PIM3L3MBTL1
SCHEMBL12616476 0.74 PIM1 (0.61) PIM1PIM2L3MBTL1
SCHEMBL12615555 0.74 HTR6 (0.43) PIM1PIM2L3MBTL1TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9321756-B2 Azole compounds as PIM inhibitors AMGEN INC. (US) 2016-04-26 — — US disclosed
US-9321756-B2 Azole compounds as PIM inhibitors AMGEN INC. (US) 2016-04-26 — — US disclosed
US-20140187553-A1 Azole Compounds as PIM Inhibitors AMGEM INC. (US) 2014-07-03 — — US disclosed
US-20140187553-A1 Azole Compounds as PIM Inhibitors AMGEM INC. (US) 2014-07-03 — — US disclosed
EP-2688886-A1 AZOLE COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2014-01-29 — — EP disclosed
WO-2012129338-A1 AZOLE COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-09-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140187553-A1 Azole Compounds as PIM Inhibitors PIM1, PIM3, PIM2 PIM1 1/4885PIM2 3/4885PIM3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback